Results 261 to 270 of about 57,705 (278)

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Nature Cancer, 2020
Pedram Razavi, Payal D Shah, Weiyi Toy
exaly  

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

New England Journal of Medicine, 2021
Michael Fx Gnant, Florian Fitzal, Christian F Singer   +2 more
exaly  

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly  

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Lancet Oncology, The, 2022
exaly  

Mechanisms of aromatase inhibitor resistance

Nature Reviews Cancer, 2015
Tomas Reinert, Izabela Chmielewska, Matthew J Ellis   +2 more
exaly  

Whole-genome analysis informs breast cancer response to aromatase inhibition

Nature, 2012
Matthew J Ellis, Dong Shen, Jingqin Luo
exaly  

Aromatase inhibitors for breast cancer: lessons from the laboratory

Nature Reviews Cancer, 2003
Stephen R D Johnston
exaly  

Aromatase Inhibitors in the Treatment of Breast Cancer

Endocrine Reviews, 2005
John C Hackett
exaly  

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

New England Journal of Medicine, 2016
James N Ingle, Julie R Gralow, Karen A Gelmon   +2 more
exaly  

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Journal of Clinical Oncology, 2008
Stephen K L Chia, Frédéric Amant, John F R Robertson   +2 more
exaly